A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

RecruitingPhase 1/2

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
* At least 1 measurable lesion per Lugano criteria.
* Tumor tissue is available.
* Adequate organ function

Exclusion Criteria:

* T-cell lymphoma
* CLL or SL
* Burkitt lymphoma and high-grade B-cell lymphoma
* CNS involvement
* Peripheral neuropathy \> Grade 2
* Uncontrolled medical conditions
* Viral infections

About the study

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

What is being tested

TORL-5-700 (drug)
TORL-5-700 at MTD/RP2D (drug)
TORL-5-700 at MTD/RP2D in combination with another agent (drug)

Sponsor: TORL Biotherapeutics, LLC · Participants: 155 · Started: Mar 31, 2026

Contact the study team

Eric Park, M.D. · Phone: (310) 598-5969

Official record on ClinicalTrials.gov — NCT07439653

Locations in the U.S.

California	Providence Medical Foundation, Fullerton Cancer and Blood Specialty Clinic, Los Alamitos, Los Alamitos UCLA, Santa Monica Stanford University, Stanford
Florida	University of California Miami, Sylvester Comprehensive Cancer Center, Miami
Iowa	University of Iowa Health Care, Iowa City
Kansas	Cancer Center of Kansas, Wichita, Wichita
Tennessee	Sarah Cannon Research Institute, Nashville
Texas	University of Texas Southwestern Medical Center, Dallas

Conditions

B-Cell Lymphoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.